Review Article| Volume 25, ISSUE 4, P591-606, November 2009

Download started.


Hyperlipidemia in Older Adults


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Geriatric Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Castelli W.P.
        • Wilson P.W.
        • Levy D.
        • et al.
        Cardiovascular risk factors in the elderly.
        Am J Cardiol. 1989; 63: 12-16
        • Katzel L.I.
        • Goldberg A.P.
        • Hazzard W.R.
        • et al.
        Principals of geriatric medicine and gerontology.
        5th edition. McGraw-Hill Inc, New York2003 (p. 875–91)
        • Grundy S.M.
        • Cleeman J.I.
        • Rifkind B.M.
        • et al.
        Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program.
        Arch Intern Med. 1999; 159: 1670
        • Kreisberg R.A.
        • Kasim S.
        Cholesterol metabolism and aging.
        Am J Med. 1987; 82: 54
        • Ferrara A.
        • Elizabeth B.C.
        • Shan J.
        Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984–1994.
        Circulation. 1997; 96: 37
        • Ericsson S.
        • Eriksson M.
        • Vitols S.
        • et al.
        Influence of age on the metabolism of plasma low density lipoproteins in healthy males.
        J Clin Invest. 1991; 87: 591
        • Wong N.D.
        • Wilson P.W.
        • Kannel W.B.
        Serum cholesterol as a prognostic factor after myocardial infarction; the Framingham Study.
        Ann Intern Med. 1991; 115: 687-693
        • Aronow W.S.
        • Ahn C.
        Correlation of serum lipids with the presence and absence of coronary artery disease in 1,793 men and women aged >62 years.
        Am J Cardiol. 1994; 73: 702-703
        • Corti M.C.
        • Guralnik J.M.
        • Salive M.E.
        • et al.
        HDL cholesterol predicts coronary heart disease mortality in older persons.
        JAMA. 1995; 274: 539
        • Aronow W.S.
        • Ahn C.
        Risk factors for new coronary events in large cohort of very elderly patients with and without coronary artery disease.
        Am J Cardiol. 1996; 77: 866
        • Corti M.C.
        • Guralnik J.M.
        • Salive M.E.
        • et al.
        Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons.
        Ann Intern Med. 1997; 126: 753
        • Grundy S.M.
        • Cleeman J.I.
        • Merz C.N.B.
        • et al.
        Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
        Circulation. 2004; 110: 227-239
        • Buckley D.A.
        • Kelber S.T.
        • Goodwin J.S.
        The use of dietary restrictions in malnourished nursing home patients.
        J Am Geriatr Soc. 1994; 42: 1100-1102
        • Wilson M.M.
        • Vaswani S.
        • Morley J.E.
        • et al.
        Prevalence and causes of undernutrition in medical outpatients.
        Am J Med. 1998; 104: 56-63
        • Lavie C.J.
        Treatment of hyperlipidemia in elderly persons with exercise training, non pharmacologic therapy and drug combinations.
        Am J Geriatr Cardiol. 2004; 13: 29-33
        • Lavie C.J.
        • Milani R.V.
        • Cassidy M.M.
        • et al.
        Benefits of cardiac rehabilitation and exercise training in older persons.
        Am J Geriatr Cardiol. 1995; 4: 42-48
        • Lavic C.J.
        • Milani R.V.
        Effects of cardiac rehabilitation programs on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in a large elderly cohort.
        Am J Cardiol. 1995; 76: 177-179
        • Milani R.V.
        • Lavie C.J.
        Prevalence and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic lifestyle change with cardiac rehabilitation.
        Am J Cardiol. 2003; 92: 50-54
        • Milani R.V.
        • Lavie C.J.
        Prevalence and effects or nonpharmacologic treatment of “isolated” low-HDL cholesterol in patients with coronary artery disease.
        J Cardiopulm Rehabil. 1995; 15: 439-444
        • Lavie C.J.
        • Milani R.V.
        Effects of nonpharmacologic therapy with cardiac rehabilitation and exercise training in patients with low levels of high-density lipoprotein cholesterol.
        Am J Cardiol. 1997; 78: 1286-1288
        • Ades P.
        • Huang D.
        • Weaver S.O.
        Cardiac rehabilitation participation predicts lower rehospitalization costs.
        Am Heart J. 1992; 123: 916-921
        • O'Connor G.T.
        • Buring J.E.
        • Yusuf S.
        • et al.
        An overview of randomized trials of rehabilitation with exercise after myocardial infarction.
        Circulation. 1989; 80: 234-244
        • Cater N.B.
        • Grundyh S.M.
        Lowering serum cholesterol with plant sterols and stanols historical perspectives.
        Postgrad Med. 1998; : 6-14
        • Miettinen T.A.
        • Puska P.
        • Gylling H.
        • et al.
        Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population.
        N Engl J Med. 1995; 333: 1306-1312
        • Gylling H.
        • Radhakrishnan R.
        • Miettinen T.A.
        Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine. Women and dietary sitostanol.
        Circulation. 1997; 96: 4226-4231
        • O'Keefe J.
        • Lavie C.J.
        Dietary prevention of coronary artery disease. How to help patients modify eating habits and reduce cholesterol.
        Postgrad Med. 1989; 85: 243-261
        • Anderson J.W.
        • Story L.
        • Sieling B.
        • et al.
        Hypercholesterolemic effects of oat-bran or bean intake for hypercholesterolemic men.
        Am J Clin Nutr. 1984; 40: 1146-1155
        • Anderson J.W.
        • Zettwoch N.
        • Feldman T.
        • et al.
        Cholesterol lowering effects of psyllium hydrophilic mucilloid for hypercholesterolemic men.
        Arch Intern Med. 1988; 148: 292-296
        • Aronow W.S.
        Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol >125 mg/dL.
        Am J Cardiol. 1998; 82: 668-674
        • Ko D.T.
        • Mamdani M.
        • Alter D.A.
        Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox.
        JAMA. 2004; 291: 1864
        • Pitt B.
        • Mancini G.B.
        • Ellis S.G.
        • et al.
        Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC 1): reduction in atherosclerosis progression and clinical events.
        J Am Coll Cardiol. 1995; 26: 1133-1139
        • Tamura A.
        • Mikuriya Y.
        • Nasu M.
        • et al.
        Effect of Pravastatin (10 mg/d) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease.
        Am J Cardiol. 1997; 79: 893-896
        • Walter D.H.
        • Schachinger V.
        • Elsner M.
        • et al.
        Effect of statin therapy on restenosis after coronary stent implantation.
        Am J Cardiol. 2000; 85: 962-968
        • Vaughan C.J.
        • Gotto A.M.
        • Basson C.T.
        The evolving role of statins in the management of atherosclerosis.
        J Am Coll Cardiol. 2000; 35: 1-10
        • Anderson T.J.
        • Meredith I.T.
        • Yeung A.C.
        • et al.
        The effect of cholesterol lowering and anti-oxidant therapy on endothelium dependant coronary vasomotion.
        N Engl J Med. 1995; 332: 488-493
        • Dupuis J.
        • Tardif J.C.
        • Cernacek P.
        • et al.
        Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of Endothelium) trial.
        Circulation. 1999; 99: 3227-3233
        • Rosenson R.S.
        • Tangney C.C.
        Antiatherothrombotic properties of statins. Implications of cardiovascular event reduction.
        JAMA. 1998; 279: 1643-1650
        • Johannesson M.
        • Jönsson B.
        • Kjekshus J.
        • et al.
        Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
        N Engl J Med. 1997; 336: 332-336
        • Shepherd J.
        • Blauw G.J.
        • Murphy M.B.
        • et al.
        Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial.
        Lancet. 2002; 360: 1623-1630
        • Shepherd J.
        • Cobbe S.M.
        • Ford I.
        • et al.
        Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
        N Engl J Med. 1995; 333: 1301-1307
        • Downs J.R.
        • Clearfield M.
        • Weis S.
        • et al.
        Primary prevention of acute coronary events with lovastatin in men and with average cholesterol levels. Results of AFCAPS/TexCAPS.
        JAMA. 1998; 279: 1615-1622
      1. SSSS Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344: 1383
        • Sacks F.M.
        • Pfeffer M.A.
        • Moye L.A.
        • et al.
        The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
        N Engl J Med. 1996; 335: 1001-1009
        • Lewis S.J.
        • Moye L.A.
        • Sacks F.M.
        • et al.
        Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.
        Ann Intern Med. 1998; 129: 681-689
        • Lewis S.J.
        • Sacks F.M.
        • Mitchell J.S.
        • et al.
        Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) trial.
        J Am Coll Cardiol. 1998; 32: 140-146
        • Neil H.A.
        • DeMicco D.A.
        • Luo D.
        • et al.
        Analysis of efficacy and safety in patients aged 65–75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
        Diabetes Care. 2006; 29: 2378
        • The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group
        Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
        N Engl J Med. 1998; 339: 1349-1357
        • Hunt D.
        • Young P.
        • Simes J.
        • For the LIPID Investigators
        • et al.
        Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial.
        Ann Intern Med. 2001; 134: 931-940
        • Tonkin A.M.
        • Eckermann S.
        • White H.
        • et al.
        Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
        Am Heart J. 2006; 151: 1305-1312
        • The Post Coronary Artery Bypass Graft Trial Investigators
        The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
        N Engl J Med. 1997; 336: 153-163
        • Burton J.R.
        • Teo K.K.
        • Buller C.E.
        • et al.
        Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT).
        Can J Cardiol. 2003; 19: 487-491
        • Alexander K.
        • Iddo Z.
        • Frida G.
        • et al.
        Declining frequency of liver enzyme abnormalities with statins: experience from general practice in Jerusalem.
        Eur J Gastroenterol Hepatol. 2008; 20: 1002-1005
        • Ballantyne C.M.
        • Corsini A.
        • Davidson M.H.
        • et al.
        Risk for myopathy with statin therapy in high-risk patients.
        Arch Intern Med. 2003; 163: 553-564
        • Lemaitre R.N.
        • Psaty B.M.
        • Heckbert S.R.
        • et al.
        Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the cardiovascular health study.
        Arch Intern Med. 2002; 162: 1395
        • Caso G.
        • Kelly P.
        • McNurlan M.A.
        • et al.
        Effect of coenzyme q10 on myopathic symptoms in patients treated with statins.
        Am J Cardiol. 2007; 99: 1409-1412
        • Ballantyne C.M.
        • Houri J.
        • Notarbartolo A.
        • et al.
        Effect of ezetimibe co-administered with atonastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized double-blind trial.
        Circulation. 2003; 107: 2409-2415
        • Sager P.T.
        • Melani L.
        • Lipka L.
        • et al.
        Effect of co-administration of ezetimibe and simvastatin on high-sensitivity C-reactive protein.
        Am J Cardiol. 2003; 92: 1414-1418
        • Kastelein J.P.
        • Akdim F.
        • Stroes E.S.
        • et al.
        Simvastatin with or without ezetimibe in familial hypercholesterolemia.
        N Engl J Med. 2008; 358: 1431-1443
        • Lavie C.J.
        • Milani R.V.
        Lipid lowering drugs: nicotinic acid. Cardiovascular Drug Therapy.
        2nd edition. W.B. Saunders Company, Philadelphia1996 (p. 1061–7)
        • Mannimen V.
        • Elo M.O.
        • Frick M.H.
        • et al.
        Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.
        JAMA. 1988; 260: 641-651
        • Milani R.V.
        • Lavie C.J.
        Lipid lowering drugs: gemfibrozil. Cardiovascular Drug Therapy.
        2nd edition. WB Saunders Company, Philadelphia1996 (p. 1098–101)
        • Bloomfield H.
        • Robins S.J.
        • Collins D.
        • et al.
        Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.
        N Engl J Med. 1999; 341: 410-418
        • Lipids Research Clinics Program
        The Lipid Research Clinics Coronary Primary Prevention Trial Results. Reduction in incidence of coronary heart disease.
        JAMA. 1984; 251: 351-364
        • Bays H.E.
        • Stein E.A.
        Pharmacotherapy for dyslipidemia: current therapies and future agents.
        Expert Opin Pharmacother. 2003; 4: 1901-1938